Aduhelm could soon represent 1% of all US healthcare spending

(By Katie Adams for Becker’s Hospital Review)

Biogen’s Alzeheimer’s drug Aduhelm could single-handedly represent 1 percent of all national healthcare expenditures by the mid-2020’s, according to a report released June 16 by research nonprofit Altarum.  Continue reading the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org